Supernus Pharmaceuticals (SUPN) Peer Comparison

$27.85

$-0.36 (-1.28%)

As on 05-Nov-2026 11:37EST

Market cap

$2,441 Mln

Revenue (TTM)

$865 Mln

P/E Ratio

--

P/B Ratio

2.3

Div. Yield

0 %

Edit

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Market cap ($ Mln)	2,441	14,600	11,755	6,434	1,262,667
Revenue ($ Mln)	865	946	331,377	254	86,462
Net Profit ($ Mln)	-43.86	-570.21	28,032.40	51.46	27,579.70
Net Margin (%)	-5.07	-60.30	8.46	20.27	31.90
RoE (%)	-4.10	--	7.51	5.25	77.18
Price to Earnings	--	--	39.19	34.01	46.11
Price-To-Book	2.30	123.68	2.91	6.65	31.35

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Operating Revenue	865.11	945.54	331,377.21	253.83	86,462.00
Cost of Revenue	107.09	61.34	167,448.74	-18.05	14,149.70
Gross Profit	644.39	473.81	190,428.00	261.50	54,127.00
Operating Expenses	789.32	1,294.12	134,367.32	241.64	32,481.90
Operating Profit (EBIT)	-30.40	-409.91	29,561.14	30.24	39,830.40
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-42.80	-578.95	35,270.62	52.73	34,769.20
Provision for Tax	1.05	-4.96	7,639.53	1.27	7,189.50
Profit after Tax (Net Income)	-43.86	-570.21	28,032.40	51.46	27,579.70
Minority Interest	0.00	11.75	401.00	0.00	0.00
Consolidated Profit	0.00	0.00	12,099.00	0.00	6,636.00

Liabilities ($ Mln)

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Shareholder's Funds	1,062.48	-1,662.34	387,871.57	961.76	40,271.00
Minority Interest	0.00	11.75	401.00	0.00	0.00
Non-Current Liabilities	49.82	2,838.05	30,754.20	1,172.05	60,805.00
Current Liabilities	285.40	977.24	155,168.12	39.76	46,996.00
Total Liabilities	1,452.65	936.03	492,989.00	1,560.64	112,476.00

Assets ($ Mln)

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Non-Current Assets	686.48	117.18	278,119.64	800.11	82,809.00
Current Assets	711.22	2,044.61	298,879.23	530.62	65,263.00
Total Assets	1,452.65	936.03	492,989.00	1,560.64	112,476.00
Total Debt*	36.20	2,494.05	72,603.83	1,128.22	49,503.00
Net Current Assets	0.00	1,067.37	143,084.00	0.00	18,267.00

Cashflow ($ Mln)

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Cash From Operating Activities	47.33	-445.91	46,428.00	49.36	16,813.00
Cash Flow from Investing Activities	4.11	-24.49	-58,077.00	-377.32	-10,972.00
Cash from Financing Activities	9.13	359.29	18,911.00	428.22	-2,213.00
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
ROCE (%)	-3.55	-159.44	16.61	10.79	35.32
ROE (%)	-4.10	41.15	7.51	5.25	77.18
ROA (%)	-2.27	-26.19	3.93	2.41	15.75
EBIT Margin (%)	-4.18	-47.10	9.79	38.83	49.24
Net Margin (%)	-5.07	-60.30	8.46	20.27	31.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Revenue Growth (%)	26.93	167.27	-3.15	1.03	45.51
EBIT Growth (%)	-106.87	34.77	-59.13	49.62	70.32
Net Profit Growth (%)	-129.41	28.47	-52.18	5.93	49.79
EPS Growth (%)	-124.42	30.63	-52.16	1.58	50.65
Book Value Growth (%)	-3.75	16.42	8.16	2.27	70.28

Valuation Ratios

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Price / Earnings	-73.93	-20.69	0.19	32.11	46.76
Price / Book Value	2.68	-7.27	0.03	3.93	36.37
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	60.71	-25.47	0.00	19.27	31.56
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Debt to Equity	0.00	-1.16	0.03	0.00	1.17
Short term debt to equity ratio	0.01	-0.33	0.16	0.00	0.06
Current Ratio	2.49	2.09	1.93	13.35	1.39
Quick Ratio	2.19	2.03	1.40	13.35	1.00
Interest Coverage	-13.11	-3.33	8.78	10.99	30.52

Operating Efficiency Ratios

	Supernus Pharmaceuticals (SUPN)	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Eli Lilly and Company (LLY)
Debtors to sales (%)	24.82	39.67	30.73	32.79	29.18
Asset Turnover	0.45	0.43	0.46	0.12	0.49
Receivable days	83.79	52.44	115.08	70.50	93.67
Inventory Days	334.77	172.81	181.99	644.28	352.51
Payable days	17.79	296.14	56.23	234.84	142.23
Cash Conversion Cycle	400.77	-70.89	240.84	479.94	303.95

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly